Tags : Lung Cancer

Johnson & Johnson Signs a License Agreement with Pulmatrix to

Shots: Pulamtrix to receive $7.2M up front, milestones up to $2M on completion of P-Ib study of RV1162/PUR1800 for patients with COPD, with on-track for year-end 2020 from J&J’s Lung Cancer. Lung Cancer Initiative to get an option to access the portfolio of kinase inhibitor targeted for lung cancer Post exercising an option, for RV1162/PUR1800 […]Read More

BMS Reports Result of Opdivo (nivolumab) + Yervoy (ipilimumab) +

Shots: The P-III CheckMate -9LA study involve assessing of Opdivo (360mg q3w) + Yervoy (1mg/kg q6w) combined with CT (two cycles) vs CT as monothx. (up to four cycles followed by optional pemetrexed maintenance therapy if eligible) as a 1L treatment in patients with advanced NSCLC regardless of PD-L1 expression and histology The P-III CheckMate […]Read More

OncoCyte to Acquire Razor Genomics for the Expansion of its

Shots: OncoCyte acquires 25% stake in Razor and has an option to acquire its remaining shares. Razor to receive $10M for initial acquiring of 25% stock in its preferred share plus $1M as milestones based on its positive CMS coverage decision with its expected closure in end of September Post exercising the option, Razor to […]Read More